Anatomy of the Introductory Email

By Lucy Parkinson, Research Manager, LSN

lucy 10*10

LSN continually stresses the importance of producing quality marketing materials. Every client is advised of best practices for investor outreach. A poor presentation can hinder even the most disruptive technology from gaining traction with investors.

Recently, an investor responded to a client’s introductory email by saying it was the best he had ever received. So here we dissect that introductory email, using generic details rather than any identifying information.

Our client’s first step was to explain who he was, that he was aware of the investor’s criteria, and why he believes that his company is a good fit.

My name is John Smith, and I am the CEO of ABC Medtech, a partner of Life Science Nation (LSN). After reviewing your investment criteria and mandate with LSN, ABC seems closely aligned with [name of investor’s organization] investment priorities. After reading the brief introduction below, please review our pitch deck for detailed information.

In his first paragraph, our client began to cut through the noise and prove the relevance of his message to the investor. The client also directed the investor’s attention to the email’s attachments.

Next, our client spelled out what he was looking for: growth-stage capital for a product that’s on the market and that has specific, measurable goals for success.

ABC is seeking growth capital to accelerate the production and sales of our game-changing medical technology and to promote our mission of decreasing mortality and reducing surgical errors in [indication area].

Our client then provided a compelling two-sentence description of the product and invited the investor to click through to the company’s website to see photos and videos of the product. By providing this means of engagement, our client was able to get the investor’s interest and obtain feedback via metrics: if an investor clicked through to the website, that’s an indication of interest that’s worth our client’s follow-up time.

In the next part of the email, our client detailed how much capital he was seeking and what the company was going to do with it to further its mission.

ABC seeks to capitalize the business with up to [amount] in capital to scale production, build inventory, accelerate commercialization, and enhance marketing and sales capabilities. 

The client also went on to briefly outline the product’s major customers, the revenue it is generating, and its projected revenue for the near future. These specifics gave the investor a solid picture of ABC Medtech’s position in only a few lines of text.

Finally, our client explained ABC’s strengths as a growth-stage device company and provided a call to action that will provoke a response.

Steady growth can be sustained without capital, but the firm risks losing its window of competitive exclusivity. ABC has limited competition and significant competitive advantages, and it is poised to dominate a rapidly growing medical market.

This email is an example of how to succinctly define an opportunity to an investor. You can’t be generic; a company in a different sector with different key talking points should introduce itself in a completely different way. It’s also important to think about what will compel each investor to act; you might make a different pitch to a charitable foundation than you would to a hedge fund. But whoever you’re speaking to, conveying every necessary detail as concisely as possible is the key to ensuring that your introduction has impact.

What impression will you make on the next investor you email?

Insurance and Healthcare Providers Invest in Early Stage Companies

By Michael Quigley, Research Manager, LSN

mike-2The formation of direct-investment arms financed by insurance companies, hospitals, and healthcare providers is a growing trend in the life sciences industry. The research team at LSN has identified at least 15 that are actively seeking opportunities at this time. And after reviewing the 10 most recent investment mandates for these organizations and speaking with them, it is clear that they all have a singular focus: reducing the cost of care. This makes sense. By investing in life science companies, these organizations can lower the costs of care and increase profitability, while establishing an equity position in a growing company. It’s a win-win approach.

Interestingly, these organizations also have very similar ideas about the types of technologies that they want to fund in order to lower the cost of care. Fifteen have stated interests in health IT, 12 in medical devices or diagnostics, and 5 in therapeutics. It would appear that the financial requirements for therapeutic assets are too large and investment timelines are too long for some of these types of investors. However, the requirements for the health IT and device sectors are more manageable—and are red hot. Furthermore, the subsectors of patient monitoring, diagnostic devices, wearable and mobile medical devices, surgical tools, hospital hardware, and elder and chronic care all come up time and time again when speaking with these investors.

These investors also are uniquely positioned to assume the role of strategic partner for early stage companies for several reasons. First, many are able to aid in the organization of clinical-trial participants, since they are healthcare providers. Second, many are able to perform a deeper level of due diligence, since they have staff who would be the end users of many of these medical products and tools. Third, these investors tend have insight into the reimbursement process and environment, which has been known to be the bane of many early stage or newly commercialized medical devices. Finally, these investors ultimately realize their ROI when your product reaches commercialization and begins to reduce the cost of care; they are not looking to reach (or force) a value inflection point so that they can sell out to other institutional investors.

Given all these factors, these direct-investment arms are excellent prospects for companies that fit the investment mandates.

Hot Life Science Investor Mandate 1: Corporate VC Arm of Device Manufacturer Looking for Early Stage Opportunities

The corporate venture capital division of a global medical device company is looking to make investments into early stage medical devices. The firm’s investments are highly varied in both size and structure; the structure may involve milestone payments, or may be an equity investment.  The firm is looking for companies located globally.

The firm invests in every class of medical devices.  The firm invests strategically in indication areas of interest to its parent company, including cardiovascular devices, diseases of the nervous system, and oncology devices.  The firms current portfolio includes cardiovascular and neurovascular devices, diabetes care, ophthalmic devices, diagnostic devices, surgical devices (including urological devices), aesthetics, and ENT devices.  The firm only invests in devices which have data from animal or human trials that provides evidence that the product will succeed; prototype-stage devices are not of interest.

The firm is looking to invests in medical device companies with competitive, patented technology and which are pursuing solutions to significant unmet medical needs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 2: Venture Arm of Health Insurance Seeking Technologies to Lower Cost of Care

The Venture investment arm of a health insurance provider is looking to acquire and grow ventures with pre-money valuations from $10M-50M. The firm will consider flexible investment structures on a case-by-case basis and seeks to launch 3-5 new ventures each year. The firm invests worldwide with special interest in geographic areas with a large population of senior citizens. The group seeks technology and services that will be available in the Massachusetts market.

The firm seeks to make strategic acquisitions and investments and is solely motivated by reducing the cost of healthcare through scientific discovery and technology. Primary areas of interest include diagnostics, monitoring, preventative medical technology, automation, hardware, and software. The group will only consider technologies with health related applications.

The firm is especially interested in technologies that will impact the senior or low-income markets, including diabetes prevention and technology that can increase access to seniors. The firm seeks low risk technology; it has not invested in biotech but would consider investments in the space. The firm seeks early stage technology still in development.

The firm seeks companies with a management team experienced in one or more of the following: new ventures, healthcare development, software, mobile technology, healthcare administration, or primary care. The group seeks companies that can benefit from reaching a wide range of users through its parent company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 3: Global PE Company Looking for Early Stage Therapeutics

A global PE company with dedicated Life Science investment funds is looking to provide seed, venture and growth capital to companies in the life science space.  The firm’s investment size is highly variable depending on the stage and financial needs of each company and the firm has no target number of investments it plans to make over the next 6-9 months. The firm is willing to consider investment located globally.

The firm is focuses on a new investment approach to developing pharmaceutical assets in a capital efficient fashion, to a human proof-of-concept in single asset companies  that are anywhere from 12-18 months to IND to proof of concept (Phase IIa). The fund is currently most interested in small molecule therapeutics or IND-ready biologics for indications of metabolic disease, diseases of the blood, inflammation, and oncology. The firm is also willing to invest in highly differentiated biological compounds if compelling opportunities arise.  The firm is also less inclined to invest into orphan indication.

The firm’s requirements for management teams vary on a case by case basis and the firm is open to discussion in this area.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 1: Debt Fund Seeking Therapeutic and Device Companies

A US-based fund seeks to provide debt financing to companies in the life science and healthcare sectors; financing is offered in the forms of senior secured term loans, cash flow loans, revolving lines of credit, real estate and equipment loans. Loans may vary in size from $500,000 to $50m, with ranges and payment terms varying according to the type of loan provided. The firm typically issues about $400-500m in debt per year. Debt is provided to companies for working capital, growth, expansions, recapitalizations, product licensing or acquisitions, or to purchase equipment or real estate. The firm considers opportunities in the USA, Canada, Europe and Oceania.

In the life science sector, the firm is most interested in companies developing therapeutics and medical devices. The firm considers lending to therapeutic companies with a product in Phase I development or later, or to device companies in clinical development or later.

The firm provides capital to both revenue generating and pre-revenue companies. Typically, capital is deployed to bring a company to the next inflection point (such as break-even or an acquisition). The firm prefers to lend to companies that have already received the backing of a number of institutional investors such as VCs.  The ability of these investors to provide follow-on financing, if necessary, is a key part of the evaluation of an opportunity. When considering management teams, the firm prefers those who have prior industry experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 2: PE Firm Seeks Devices and Diagnostics

A US-based private equity firm founded in 2000 is actively investing from two funds. The firm currently has $150M in AUM. The group typically invests from $8M – 20M over the lifetime of an investment and anticipates investments in 2 – 3 platforms over the next year. Investments in the United States and Canada are of interest.

The firm primarily considers medical devices and diagnostics that overlap with or contribute to the healthcare IT and service landscapes, where they predominantly invest. The firm will consider all classes of medical devices. The group is agnostic in terms of indication.

The firm seeks a board seat and is extremely involved in management of portfolio companies. The group seeks a strong management team that has scaled a company in the past. The group prefers to leads investments but will consider co-investing. Growth-stage companies with products already on the market are the core focus of the firm. Though the firm prefers a positive cash flow, it will consider companies not yet making a profit, if the company has a controlled burn rate. The group will also consider add-on devices not yet on the market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com